MASH, also known as nonalcoholic steatohepatitis (NASH), is a chronic and progressive condition that represents a severe form of metabolic dysfunction-associated steatotic liver disease (MASLD). It is ...

Denifanstat Phase 2b FASCINATE-2 clinical data to be presented as an oral presentation at the EASL International Liver Congress 2024 taking place ...

Limiting sweets, red meat, fast food, and heavily processed foods can all help prevent metabolic dysfunction–associated ...

I began medical school many years ago – way back in the 1990s. Back then, “Friends” was a top TV show, Jordan was winning ...

Operator: Good afternoon, ladies and gentlemen, and welcome to the Relmada Therapeutics Inc. First Quarter 2024 Financial ...

One meta-analysis observed a 3.55 mm Hg decrease in systolic blood pressure and a 1.32 mm Hg reduction in diastolic blood ...

SLIM LIVER was the first study evaluating semaglutide as a treatment for MASLD among people living with HIV. MASLD is common ...

In March 2024, Akero announced the closing of its upsized, underwritten public offering of 12,650,000 shares of its common stock at a public offering price of $29.00 per share, which included the ...

A recent clinical trial conducted by researchers from Massachusetts General Hospital and published in JAMA offers new hope in the fight against metabolic dysfunction-associated steatotic liver disease ...

"As we continue to see a rise in metabolic syndrome in the US, MASLD is becoming more and more prominent," stated Dr. Marion ...

Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic ...